DBV Technologies
Most recent annual filing: 2026-03-15
- Viaskin Peanut 4-7 year-olds BLA3Q 2026Viaskin Peanut 4-7 year-olds BLA, 3Q 2026, material
- Viaskin Peanut Toddlers 1-3yo BLA2H 2026Viaskin Peanut Toddlers 1-3yo BLA, 2H 2026, material
- Toddler BLA ages 1-3 filing2H 2026Toddler BLA ages 1-3 filing, 2H 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Viaskin Milk
VIASKIN milk patch · DBV135Technology platforms
Viaskin
Epicutaneous immunotherapy (EPIT) patch delivery platform; designed to re-educate the immune system via skin-based antigen delivery; focus area: food allergies and other immunological diseases including peanut allergy and cow's milk allergy
Discontinued (1)
- Viaskin Milk — Eosinophilic Esophagitis
Biotech Distilled coverage (7)
- 2026-08-07 UPDATE: DBV Technologies (DBVT) - Who Bought the $50M 🔒 Paid
- 2026-07-31 UPDATE: DBV Technologies (DBVT) - They Used the ATM. Fast. 🔒 Paid
- 2026-07-17 UPDATE: DBV Technologies (DBVT) - The ATM Refills, One Day After the Warning Letter 🔒 Paid
- 2026-07-16 UPDATE: DBV Technologies (DBVT) - The Warning Letter Buried in the 10-Q
- 2026-06-29 UPDATE: DBV Technologies (DBVT) - The BLA Slips a Quarter
- 2026-03-28 UPDATE: DBV Technologies (DBVT) - FDA Hits Fast Forward 🔒 Paid
- 2025-12-22 DBV Technologies (DBVT): Scientific Due Diligence 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.